FibroGen Inc. DEF 14A Filing

TL;DR

<b>FibroGen Inc. files DEF 14A detailing executive compensation and equity award valuations for the 2023 fiscal year.</b>

AI Summary

FIBROGEN INC (KYNB) filed a Proxy Statement (DEF 14A) with the SEC on April 24, 2024. Filing is a DEF 14A from FibroGen Inc. on 2024-04-24. The report covers the fiscal year ending December 31, 2023. Key data points relate to the fair value of equity awards granted in prior fiscal years. Specific metrics include changes in fair value of unvested equity awards and awards that failed to meet vesting conditions. The filing also details dividend or other earnings paid on stock or option awards.

Why It Matters

For investors and stakeholders tracking FIBROGEN INC, this filing contains several important signals. This filing provides crucial information for shareholders regarding executive compensation structures and the valuation of equity awards, impacting potential dilution and incentive alignment. Understanding the changes in fair value of equity awards, especially those that failed to vest, can offer insights into the company's performance and the effectiveness of its incentive programs.

Risk Assessment

Risk Level: low — FIBROGEN INC shows low risk based on this filing. The filing is a routine DEF 14A, providing disclosures on executive compensation and equity awards rather than material business events.

Analyst Insight

Review the executive compensation details and equity award valuations to understand potential shareholder dilution and management incentives.

Key Numbers

• 2023-12-31 — Fiscal Year End (Covered fiscal year)
• 2024-04-24 — Filing Date (Date of filing)
• 2020-01-01 to 2023-12-31 — Reporting Period for Equity Awards (Various periods covered for equity award valuations)

Key Players & Entities

• FIBROGEN INC (company) — Filer name
• DEF 14A (document) — Form type
• 2024-04-24 (date) — Filing date
• 0000921299 (company) — Central Index Key
• 2834 (industry) — Standard Industrial Classification for Pharmaceutical Preparations
• DE (location) — State of incorporation
• 1231 (date) — Fiscal year end
• 415-978-1200 (phone) — Business phone number

FAQ

Industry Context

FibroGen Inc. operates in the pharmaceutical preparations industry, focusing on the development of therapeutics.

Regulatory Implications

The DEF 14A filing is a disclosure document required by the SEC for public companies, particularly concerning proxy solicitations for shareholder meetings.

What Investors Should Do

1. Analyze the specific dollar values and percentage changes related to equity awards.
2. Examine the reasons provided for changes in fair value of equity awards.
3. Compare the disclosed equity award valuations with previous filings if available.

Key Dates

• 2024-04-24: Filing Date — Submission of DEF 14A
• 2023-12-31: Fiscal Year End — Period covered by financial disclosures

Year-Over-Year Comparison

This filing is a DEF 14A, which typically contains information on executive compensation and corporate governance, and does not represent a change in the company's core financial reporting like an 8-K or 10-Q.

Filing Documents

• fgen-20240424.htm (DEF 14A) — 2697KB
• img65688969_0.jpg (GRAPHIC) — 91KB
• img65688969_1.jpg (GRAPHIC) — 20KB
• img65688969_2.jpg (GRAPHIC) — 45KB
• img65688969_3.jpg (GRAPHIC) — 202KB
• img65688969_4.jpg (GRAPHIC) — 163KB
• img65688969_5.jpg (GRAPHIC) — 192KB
• img65688969_6.jpg (GRAPHIC) — 18KB
• img65688969_7.jpg (GRAPHIC) — 522KB
• img65688969_8.jpg (GRAPHIC) — 410KB
• 0000950170-24-047694.txt (&nbsp;) — 7566KB
• fgen-20240424.xsd (EX-101.SCH) — 38KB
• fgen-20240424_htm.xml (XML) — 357KB

From the Filing

DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under 240.14a-12 FibroGen, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. FIBROGEN, INC. 409 Illinois Street San Francisco, CA 94158 NOTICE OF A NNUAL MEETING OF STOCKHOLDERS To Be Held On June 5, 2024 Dear Stockholder: You are cordially invited to attend the 2024 Annual Meeting Stockholders (the "Annual Meeting") of FibroGen, Inc., a Delaware corporation (also referred to as "we," "us," "FibroGen," and the "Company"). The Annual Meeting will be held via live audio webcast on the internet. You will be able to attend the Annual Meeting online, vote your shares electronically, and submit your questions during the meeting by visiting www.virtualshareholdermeeting.com/FGEN2024. The Annual Meeting will be held on Wednesday, June 5, 2024 at 8:00 a.m. Pacific Time for the following purposes: 1. To elect our Class I director nominees, Thane Wettig, James A. Schoeneck, and Maykin Ho, Ph.D., to our board of directors to hold office until the 2027 annual meeting of stockholders. 2. To approve the FibroGen, Inc. 2024 Equity Incentive Plan. 3. To approve, on an advisory basis, the compensation of the Company's named executive officers. 4. To ratify the selection, by the Audit Committee of our board of directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2024. 5. To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers. 6. To conduct any other business properly brought before the meeting. These items of business are more fully described in the proxy statement accompanying this notice. The record date for the Annual Meeting is April 8, 2024 (the "Record Date"). Only stockholders of record at the close of business on that date may vote by proxy or at the Annual Meeting (live audio webcast) or any adjournment thereof. Please see the attached proxy statement for information on how to vote by proxy and how to attend and vote at the Annual Meeting. A list of our record stockholders entitled to vote as of the close of business on the Record Date will be available for review during regular business hours at our principal executive offices at 409 Illinois Street, San Francisco, California 94158 for ten days prior to the Annual Meeting for any legally valid purpose related to the Annual Meeting, and will available during the entire time of the Annual Meeting at www.virtualshareholdermeeting.com/FGEN2024 . Important Notice Regarding the Availability of Proxy Materials for the Annual Stockholders' Meeting The proxy statement and Annual Report on Form 10-K are available at www.proxyvote.com . By Order of the Board of Directors April 24, 2024 Your vote is very important. Whether or not you expect to attend the Annual Meeting, please vote online or by telephone prior to the Annual Meeting as instructed in these materials, or if you requested and received a proxy by mail, please complete, date, sign, and return the proxy as promptly as possible in order to ensure your representation at the Annual Meeting. Even if you have voted by proxy, you may still vote online if you attend the Annual Meeting. Please review the section below " How do I vote? " for specific instructions on voting your shares before and during the Annual Meeting. Table of Contents Information Concerning Solicitation and Voting 1 Special Note Regarding Forward-Looking Statements 8 Proposal 1 – Election of Directors 9 Directors and Corporate Governance 13 Proposal 2 – Approval of the FibroGen, Inc. 2024 Equity Incentive Plan 26 Proposal 3 – Advisory Vote on Named Executive Officer Compensation 34 Proposal 4 – Ratification of Selection of Independent Registered Public Accounting Firm 35 Proposal 5 – Advisory Vote on Frequency of Solicitation of Advisory Stockholder Approval of Executive Compensation 37 Report of the Audit Committee of the Board of Directors 38 Executive Officers 39 Compensation Discussion and Analysis 40 Compensation Committee Report 63 Summary Compensation 64 Pay Versus Perform

View Full Filing

View this DEF 14A filing on SEC EDGAR